Zanubrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL
ConditionDLBCL
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorRuijin Hospital
About this trial
This trial is a prospective, single-center, randomized controlled clinical research. The intention is to evaluate the efficacy and safety of zanubrutinib combined with BEAM as a pretreatment regimen for ASCT in relapsed and refractory DLBCL patients through prospective clinical studies.
Eligibility criteria
Qualifiers
According to world Health Organization (WHO) classification of disease, diffuse large B-cell lymphoma was confirmed by histology, CR or PR after second-line and above treatment;
18≤ age ≤65 years old, male or female;
ECOG score 0-2;
White blood cell count ≥3.0×109/L, absolute neutrophil count ≥1.5×109/L, Hemoglobin ≥90g/L, platelet ≥75×109/L;
Disqualifiers
Previously received autologous hematopoietic stem cell transplantation;
Suffering from serious complications or severe infection;
Previous treatment with selinexor;
Central nervous system lymphoma was excluded;
Trial design
Treatments tested in this trial
- zanubrutinib combined with BEAM
- BEAM
Treatment groups
66 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov